NTX-001 is under clinical development by Neuraptive Therapeutics and currently in Phase II for Peripheral Nerve Injury. According to GlobalData, Phase II drugs for Peripheral Nerve Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NTX-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NTX-001 overview
NTX-001 is under development for the treatment of peripheral nerve injury and gap injury. It is a combination of existing drug and device. It is administered through topical route.
Neuraptive Therapeutics overview
Neuraptive Therapeutics is a biotechnology company developing therapeutics and medical devices to treat peripheral nerve injuries. It is investigating NTX-001, a novel delivery device, a formulation and a kit designed for surgical nerve repairs after trauma; and face and body reconstructive procedures; and NTX-002, a nerve repair device. It is also developing microsurgical instruments for use in peripheral nerve surgery. The company was funded by New Rhein Healthcare investors and Ben Franklin Technology Partners. Neuraptive Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of NTX-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
